Influenza vaccine immunogenicity in patients with primary central nervous system malignancy.

ABSTRACT:

Background

Patients with central nervous system (CNS) malignancies represent an "at-risk" population for contracting influenza, particularly if they are receiving ongoing chemotherapy, radiation, and/or glucocorticoid treatment. The Centers for Disease Control endorses vaccination for these patients, although data are not available to indicate whether they mount an immunologic response adequate to achieve clinical protection.

Methods

A pilot prospective cohort study was designed to evaluate the immunogenicity of the standard-dose trivalent inactivated influenza vaccine in patients with malignant CNS tumors. Baseline data collection included diagnosis, chemotherapy, timing of chemotherapy or radiation relative to vaccination, and glucocorticoid dose. Serum samples were collec

SUBMITTER: Strowd RE 

PROVIDER: S-EPMC4232079 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature